A recent study, “Real‑World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease‑Modifying Treatments,” showed that in routine practice, approved NMOSD therapies reduce relapse rates and offer better safety than older treatments, reinforcing their value for patients. (Read the article here: pmc.ncbi.nlm.nih.gov)
To mark NMO Awareness Month 2026, we’ll be joined by Dr. Shamik Bhattacharyya, a lead author of this study, who will discuss the benefits of FDA-approved NMOSD therapies versus non-approved first-line treatments.
Join us on Thursday, March 26th at 4 PM PST / 7 PM EST. Attendees joining live will have the opportunity to participate in the live Q&A.
The webinar will be recorded and available for replay. Registration is required.
This educational program is made possible with support from Amgen and Alexion.
